CSL CSL Limited

By Josh Beckerman

Arcturus Therapeutics Holdings Inc. shares rose 26% to $23.10 after hours as the company announced a vaccine collaboration with CSL Ltd.'s CSL Seqirus.

Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and more than $3 billion in commercial milestones.

In addition, it is eligible to receive a 40% net profit share for Covid-19 vaccine products and up to double-digit royalties for certain other vaccines.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

November 01, 2022 19:12 ET (23:12 GMT)

CSL (ASX:CSL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024

CSL (ASX:CSL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024